293 related articles for article (PubMed ID: 28165651)
1. SOX2 is required to maintain cancer stem cells in ovarian cancer.
Wen Y; Hou Y; Huang Z; Cai J; Wang Z
Cancer Sci; 2017 Apr; 108(4):719-731. PubMed ID: 28165651
[TBL] [Abstract][Full Text] [Related]
2. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
Choi EJ; Seo EJ; Kim DK; Lee SI; Kwon YW; Jang IH; Kim KH; Suh DS; Kim JH
Oncotarget; 2016 Jan; 7(3):3506-19. PubMed ID: 26654944
[TBL] [Abstract][Full Text] [Related]
3. Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells.
Kim DK; Seo EJ; Choi EJ; Lee SI; Kwon YW; Jang IH; Kim SC; Kim KH; Suh DS; Seong-Jang K; Lee SC; Kim JH
Exp Mol Med; 2016 Aug; 48(8):e255. PubMed ID: 27561949
[TBL] [Abstract][Full Text] [Related]
4. XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.
Ji J; Yu Y; Li ZL; Chen MY; Deng R; Huang X; Wang GF; Zhang MX; Yang Q; Ravichandran S; Feng GK; Xu XL; Yang CL; Qiu MZ; Jiao L; Yang D; Zhu XF
Theranostics; 2018; 8(6):1494-1510. PubMed ID: 29556337
[No Abstract] [Full Text] [Related]
5. Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma.
Roudi R; Madjd Z; Ebrahimi M; Najafi A; Korourian A; Shariftabrizi A; Samadikuchaksaraei A
Tumour Biol; 2016 Sep; 37(9):11843-11859. PubMed ID: 27048287
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
Zhang S; Cui B; Lai H; Liu G; Ghia EM; Widhopf GF; Zhang Z; Wu CC; Chen L; Wu R; Schwab R; Carson DA; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17266-71. PubMed ID: 25411317
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
Li Y; Chen K; Li L; Li R; Zhang J; Ren W
Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
[TBL] [Abstract][Full Text] [Related]
8. A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.
Samardzija C; Luwor RB; Volchek M; Quinn MA; Findlay JK; Ahmed N
Mol Cancer; 2015 Aug; 14():152. PubMed ID: 26260289
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
Keysar SB; Le PN; Miller B; Jackson BC; Eagles JR; Nieto C; Kim J; Tang B; Glogowska MJ; Morton JJ; Padilla-Just N; Gomez K; Warnock E; Reisinger J; Arcaroli JJ; Messersmith WA; Wakefield LM; Gao D; Tan AC; Serracino H; Vasiliou V; Roop DR; Wang XJ; Jimeno A
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
[TBL] [Abstract][Full Text] [Related]
10. Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition.
Zhang J; Wang W; Qian L; Zhang Q; Lai D; Qi C
Oncol Rep; 2015 Nov; 34(5):2375-84. PubMed ID: 26323892
[TBL] [Abstract][Full Text] [Related]
11. CHI3L1 results in poor outcome of ovarian cancer by promoting properties of stem-like cells.
Lin HW; Chiang YC; Sun NY; Chen YL; Chang CF; Tai YJ; Chen CA; Cheng WF
Endocr Relat Cancer; 2019 Jan; 26(1):73-88. PubMed ID: 30121622
[TBL] [Abstract][Full Text] [Related]
12. Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells.
Dorsett KA; Jones RB; Ankenbauer KE; Hjelmeland AB; Bellis SL
J Ovarian Res; 2019 Oct; 12(1):93. PubMed ID: 31610800
[TBL] [Abstract][Full Text] [Related]
13. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
[TBL] [Abstract][Full Text] [Related]
14. Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance.
Ward Rashidi MR; Mehta P; Bregenzer M; Raghavan S; Fleck EM; Horst EN; Harissa Z; Ravikumar V; Brady S; Bild A; Rao A; Buckanovich RJ; Mehta G
Neoplasia; 2019 Aug; 21(8):822-836. PubMed ID: 31299607
[TBL] [Abstract][Full Text] [Related]
15. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
16. SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.
Lyu T; Jiang Y; Jia N; Che X; Li Q; Yu Y; Hua K; Bast RC; Feng W
Int J Cancer; 2020 Mar; 146(6):1553-1567. PubMed ID: 31503345
[TBL] [Abstract][Full Text] [Related]
17. LncRNA MALAT1 increases the stemness of gastric cancer cells via enhancing SOX2 mRNA stability.
Xiao Y; Pan J; Geng Q; Wang G
FEBS Open Bio; 2019 Jul; 9(7):1212-1222. PubMed ID: 31037832
[TBL] [Abstract][Full Text] [Related]
18. β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids.
Condello S; Morgan CA; Nagdas S; Cao L; Turek J; Hurley TD; Matei D
Oncogene; 2015 Apr; 34(18):2297-308. PubMed ID: 24954508
[TBL] [Abstract][Full Text] [Related]
19. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
[TBL] [Abstract][Full Text] [Related]
20. Personalized Medicine-Based Approach to Model Patterns of Chemoresistance and Tumor Recurrence Using Ovarian Cancer Stem Cell Spheroids.
Raghavan S; Mehta P; Ward MR; Bregenzer ME; Fleck EMA; Tan L; McLean K; Buckanovich RJ; Mehta G
Clin Cancer Res; 2017 Nov; 23(22):6934-6945. PubMed ID: 28814433
[No Abstract] [Full Text] [Related]
[Next] [New Search]
